drugset / Trial / NCT06445257
A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSL
Unknown
30 enrolled
Huai'an First People's Hospital
Affiliated Hospital of Nantong University · collabNorthern Jiangsu People's Hospital · collabThe Affiliated Hospital of Xuzhou Medical University · collabThe First People's Hospital of Changzhou · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a prospective, multicenter, open-label, single-arm clinical trial evaluating the safety and efficacy of the ZRMT (Zanubrutinib-Rituximab-Methotrexate-Temozolomide) regimen in the treatment of primary central nervous system lymphoma (PCNSL) with diffuse large B-cell lymphoma. This study includes an induction phase for PCNSL ± ASCT and a sequential maintenance phase.
Timeline
- Start
- 2023-09-15
- Primary completion
- 2026-04-13
- Completion
- 2026-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Methotrexate | Small molecule | 3 g | Intravenous |
| Subject | Methotrexate | Small molecule | 3.5 g | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Subject | Temozolomide | Small molecule | 100 mg | — |
| Subject | Zanubrutinib | Small molecule | 160 mg | Oral |